Design: Prospective observational study for 12 months from 5/30/2023-5/30/2024

Setting: Private practice office

Patients or Participants: Women aged 18 and older meeting the inclusion criteria and being scheduled to undergo office hysteroscopy for diagnosis and treatment purposes were enrolled in our study The inclusion criteria includes abnormal uterine bleeding, heavy menstrual, postmenopausal bleeding, abnormal pelvic ultrasound with abnormal endometrial thickening and /or intrauterine lesions. The exclusion criteria includes pregnancy, active pelvic infection, confirmed cervical and endometrial cancer. Women who withdrew voluntarily from the study were also excluded.

Interventions: All subjects were asked to complete patient-reported outcomes questionnaires: EuroQoL-5D-5L questionnaires and then to rate their overall health on the scale of EQ-VAS before hysteroscopy, 2-weeks post-hysteroscopy, and 6-8 weeks post-hysteroscopy respectively.

Measurements and Main Results: A total of 123 women were enrolled in our ongoing study, of which 91 women have completed the study ( N=91), 17 women were in the time frame to be followed, and 15 women who met the exclusion criteria or withdrew voluntarily from the study were excluded from our study. HRQoL scores showed statistically significant improvement in the anxiety/depression dimension of EQ-5D-5L between pre-hysteroscopy and 2 weeks post-hysteroscopy, pre-hysteroscopy and 6-8 weeks post-hysteroscopy (both P < 0.01). Table 1. The overall health in EQ-VAS scores were also statistically significantly improved between pre-hysteroscopy and 2-weeks post-hysteroscopy ( P<0.05); pre-hysteroscopy and 6-8 weeks post-hysteroscopy (P<0.01). Table 2.

Conclusion: Office hysteroscopy exerts positive effects on HRQoL in patients requiring the procedure and improves affected patients’ quality of life.